Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors

References

• Yao JC, Hassan M, Phan A et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26(18), 3063–3072 (2008).
   PubMed Web of Science ®Google Scholar
• Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B, Modlin IM. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol. Metab. Clin. North Am. 40(1), 111–134, viii (2011).
   PubMed Web of Science ®Google Scholar
• Hauso O, Gustafsson BI, Kidd M et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 113(10), 2655–2664 (2008).
   PubMed Web of Science ®Google Scholar
• O’Toole D, Grossman A, Gross D et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 90(2), 194–202 (2009).
   PubMed Web of Science ®Google Scholar
• Klöppel G, Couvelard A, Perren A et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 90(2), 162–166 (2009).
   PubMed Web of Science ®Google Scholar
• Clark OH, Benson AB 3rd, Berlin JD et al.; NCCN Neuroendocrine Tumors Panel Members. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J. Natl Compr. Canc. Netw. 7(7), 712–747 (2009).
   PubMedGoogle Scholar
• Oberg K, Jelic S; ESMO Guidelines Working Group. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 19(Suppl. 2), ii104–ii105 (2008).
   PubMedGoogle Scholar
• Ramage JK, Davies AH, Ardill J et al.; UKNETwork for Neuroendocrine Tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 54(Suppl. 4), iv1–i16 (2005).
   PubMed Web of Science ®Google Scholar
• Vinik AI, Woltering EA, Warner RR et al.; North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 39(6), 713–734 (2010).
   PubMed Web of Science ®Google Scholar
• Kocha W, Maroun J, Kennecke H et al. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr. Oncol. 17(3), 49–64 (2010).
   PubMed Web of Science ®Google Scholar
• Janson ET, Sørbye H, Welin S et al. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol. 49(6), 740–756 (2010).
   PubMed Web of Science ®Google Scholar
• Modlin IM, Oberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9(1), 61–72 (2008).
   PubMed Web of Science ®Google Scholar
• Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A – biological function and clinical utility in neuro endocrine tumor disease. Ann. Surg. Oncol. 17(9), 2427–2443 (2010).
   PubMed Web of Science ®Google Scholar
• Konecki DS, Benedum UM, Gerdes HH, Huttner WB. The primary structure of human chromogranin A and pancreastatin. J. Biol. Chem. 262(35), 17026–17030 (1987).
   PubMed Web of Science ®Google Scholar
• Bajetta E, Ferrari L, Martinetti A et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86(5), 858–865 (1999).
   PubMed Web of Science ®Google Scholar
• Baudin E, Gigliotti A, Ducreux M et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br. J. Cancer 78(8), 1102–1107 (1998).
   PubMedGoogle Scholar
• Baudin E, Bidart JM, Bachelot A et al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann. Oncol. 12(Suppl. 2), S79–S82 (2001).
   PubMed Web of Science ®Google Scholar
• Belli SH, Oneto A, Aranda C et al. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina. Acta Gastroenterol. Latinoam. 39(3), 184–189 (2009).
   PubMedGoogle Scholar
• Berkovic MC, Jokic M, Marout J, Radosevic S, Zjacic-Rotkvic V, Kapitanovic S. IL-2-330 T/G SNP and serum values – potential new tumor markers in neuroendocrine tumors of the gastrointestinal tract and pancreas (GEP-NETs). J. Mol. Med. 88(4), 423–429 (2010).
   PubMedGoogle Scholar
• Campana D, Nori F, Piscitelli L et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J. Clin. Oncol. 25(15), 1967–1973 (2007).
   PubMed Web of Science ®Google Scholar
• Cimitan M, Buonadonna A, Cannizzaro R et al. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann. Oncol. 14(7), 1135–1141 (2003).
   PubMed Web of Science ®Google Scholar
• Nehar D, Lombard-Bohas C, Olivieri S et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin. Endocrinol. 60(5), 644–652 (2004).
   PubMed Web of Science ®Google Scholar
• Nobels FR, Kwekkeboom DJ, Coopmans W et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J. Clin. Endocrinol. Metab. 82(8), 2622–2628 (1997).
   PubMed Web of Science ®Google Scholar
• Panzuto F, Severi C, Cannizzaro R et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J. Endocrinol. Invest. 27(1), 6–11 (2004).
   PubMedGoogle Scholar
• Peracchi M, Conte D, Gebbia C et al. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur. J. Endocrinol. 148(1), 39–43 (2003).
   PubMedGoogle Scholar
• Rodrigues M, Gabriel M, Heute D, Putzer D, Griesmacher A, Virgolini I. Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe 1-Tyr 3-octreotide and chromogranin A assay in patients with neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 35(10), 1796–1802 (2008).
   PubMedGoogle Scholar
• Schürmann G, Raeth U, Wiedenmann B, Buhr H, Herfarth C. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract. World J. Surg. 16(4), 697–701; discussion 701 (1992).
   PubMedGoogle Scholar
• Stivanello M, Berruti A, Torta M et al. Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann. Oncol. 12(Suppl. 2), S73–S77 (2001).
   PubMed Web of Science ®Google Scholar
• Tomassetti P, Migliori M, Simoni P et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur. J. Gastroenterol. Hepatol. 13(1), 55–58 (2001).
   PubMed Web of Science ®Google Scholar
• Zatelli MC, Torta M, Leon A et al.; Italian CromaNet Working Group. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. Endocr. Relat. Cancer 14(2), 473–482 (2007).
   PubMed Web of Science ®Google Scholar
• Arnold R, Wilke A, Rinke A et al. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin. Gastroenterol. Hepatol. 6(7), 820–827 (2008).
   PubMed Web of Science ®Google Scholar
• Massironi S, Conte D, Sciola V et al. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors. Am. J. Gastroenterol. 105(9), 2072–2078 (2010).
   PubMed Web of Science ®Google Scholar
• Woltering EA, Hilton RS, Zolfoghary CM et al. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency. Pancreas 33(3), 250–254 (2006).
   PubMedGoogle Scholar
• Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 39(5), 649–653 (1996).
   PubMed Web of Science ®Google Scholar
• Syversen U, Ramstad H, Gamme K, Qvigstad G, Falkmer S, Waldum HL. Clinical significance of elevated serum chromogranin A levels. Scand. J. Gastroenterol. 39(10), 969–973 (2004).
   PubMed Web of Science ®Google Scholar
• Jianu CS, Fossmark R, Syversen U, Hauso Ø, Waldum HL. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia. Tumour Biol. 31(5), 373–380 (2010).
   PubMed Web of Science ®Google Scholar
• Elias AN, Wilson AF, Pandian MR, Kayaleh R. Chromogranin A concentrations in plasma of physically active men after acute exercise. Clin. Chem. 38(11), 2348–2349 (1992).
   PubMedGoogle Scholar
• Qvigstad G, Sandvik AK, Brenna E, Aase S, Waldum HL. Detection of chromogranin A in human gastric adenocarcinomas using a sensitive immunohistochemical technique. Histochem. J. 32(9), 551–556 (2000).
   PubMedGoogle Scholar
• Waldum HL, Aase S, Kvetnoi I et al. Neuroendocrine differentiation in human gastric carcinoma. Cancer 83(3), 435–444 (1998).
   PubMed Web of Science ®Google Scholar
• Molina R, Alvarez E, Aniel-Quiroga A et al. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumour Biol. 32(1), 13–22 (2011).
   PubMedGoogle Scholar
• Abou-Saif A, Gibril F, Ojeaburu JV et al. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Cancer 98(2), 249–261 (2003).
   PubMed Web of Science ®Google Scholar
• Moattari AR, Deftos LJ, Vinik AI. Effects of sandostatin on plasma chromogranin-A levels in neuroendocrine tumors. J. Clin. Endocrinol. Metab. 69(4), 902–905 (1989).
   PubMedGoogle Scholar
• Ronchi CL, Peracchi M, Corbetta S et al. Evaluation of IGF-I levels during long-term somatostatin analogs treatment in patients with gastroenteropancreatic endocrine tumors. J. Endocrinol. Invest. 30(3), 241–246 (2007).
   PubMedGoogle Scholar
• Stridsberg M, Eriksson B, Fellström B, Kristiansson G, Tiensuu Janson E. Measurements of chromogranin B can serve as a complement to chromogranin A. Regul. Pept. 139(1–3), 80–83 (2007).
   PubMedGoogle Scholar
• Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J. Endocrinol. 177(2), 337–341 (2003).
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Cristaldi E, Cammalleri L et al. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer. Arch. Gerontol. Geriatr. 48(2), 213–217 (2009).
   PubMedGoogle Scholar
• Grozinsky-Glasberg S, Kaltsas G, Gur C et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur. J. Endocrinol. 159(4), 475–482 (2008).
   PubMed Web of Science ®Google Scholar
• Nikou GC, Lygidakis NJ, Toubanakis C et al. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues. Hepatogastroenterology 52(63), 731–741 (2005).
   PubMedGoogle Scholar
• Janson ET, Holmberg L, Stridsberg M et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann. Oncol. 8(7), 685–690 (1997).
   PubMed Web of Science ®Google Scholar
• Nikou GC, Marinou K, Thomakos P et al. Chromogranin a levels in diagnosis, treatment and follow-up of 42 patients with non-functioning pancreatic endocrine tumours. Pancreatology 8(4–5), 510–519 (2008).
   PubMed Web of Science ®Google Scholar
• Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br. J. Surg. 96(2), 175–184 (2009).
   PubMed Web of Science ®Google Scholar
• Nykjaer KM, Grønbaek H, Nielsen DT, Christiansen P, Astrup LB. Description of patients with midgut carcinoid tumours: clinical database from a Danish centre. In Vivo 21(4), 679–684 (2007).
   PubMed Web of Science ®Google Scholar
• Kouvaraki MA, Ajani JA, Hoff P et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol. 22(23), 4762–4771 (2004).
   PubMed Web of Science ®Google Scholar
• Bajetta E, Rimassa L, Carnaghi C et al. 5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer 83(2), 372–378 (1998).
   PubMed Web of Science ®Google Scholar
• Jacobs CB, Phan AT, Wolff RA, Meric-Bernstam F, Yao JC. Early CgA response as predictor of outcome following everolimus therapy among patients with low- to intermediate-grade neuroendocrine carcinoma: analyses of a single institution Phase II study. Pancreas 39, 273 (2010).
   Google Scholar
• Jensen EH, Kvols L, McLoughlin JM et al. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann. Surg. Oncol. 14(2), 780–785 (2007).
   PubMedGoogle Scholar
• Korse CM, Bonfrer JM, Aaronson NK, Hart AA, Taal BG. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine tumors. Neuroendocrinology 89(3), 296–301 (2009).
   PubMedGoogle Scholar
• Namwongprom S, Wong FC, Tateishi U, Kim EE, Boonyaprapa S. Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors. Ann. Nucl. Med. 22(4), 237–243 (2008).
   PubMedGoogle Scholar
• Pirker RA, Pont J, Pöhnl R, Schütz W, Griesmacher A, Müller MM. Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours. Clin. Chem. Lab. Med. 36(11), 837–840 (1998).
   PubMedGoogle Scholar
• Welin S, Stridsberg M, Cunningham J et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 89(3), 302–307 (2009).
   PubMed Web of Science ®Google Scholar
• Ahmed A, Turner G, King B et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr. Relat. Cancer 16(3), 885–894 (2009).
   PubMed Web of Science ®Google Scholar
• Bergestuen DS, Aabakken L, Holm K, Vatn M, Thiis-Evensen E. Small intestinal neuroendocrine tumors: prognostic factors and survival. Scand. J. Gastroenterol. 44(9), 1084–1091 (2009).
   PubMed Web of Science ®Google Scholar
• Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin. Cancer Res. 16(3), 978–985 (2010).
   PubMed Web of Science ®Google Scholar
• Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH. Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors. Dig. Dis. Sci. 51(5), 877–884 (2006).
   PubMedGoogle Scholar
• Yao JC, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a Phase II trial. J. Clin. Oncol. 28(1), 69–76 (2010).
   PubMed Web of Science ®Google Scholar
• Oberg K, Kulke M, Pavel M et al. Evaluation of chromogranin A and neuron-specific enolase as predictors of response to everolimus therapy in patients with advanced pancreatic neuroendocrine tumors (pNET). Pancreas 40, 325–336 (2011).
   Google Scholar
• Oberg K, Anthony L, Sideris L et al. Role of chromogranin A and neuron-specific enolase biomarkers in progression-free survival with everolimus versus placebo in patients with advanced pancreatic neuroendocrine tumors: Phase III RADIANT-3 results. Presented at: 8th Annual Meeting of the European Neuroendocrine Society. Lisbon, Portugal, 9–11 March 2011 (Poster C81).
   Google Scholar
• Tiensuu Janson EM. Carcinoid tumors: clinical aspects and the use of somatostatin analogues for characterization and treatment [dissertation]. Uppsala University, Stockholm, Sweden (1995).
   Google Scholar
• Tiensuu Janson EM, Oberg KE. Carcinoid tumours. Baillieres Clin. Gastroenterol. 10(4), 589–601 (1996).
   PubMedGoogle Scholar
• Turner NC, Strauss SJ, Sarker D et al. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br. J. Cancer 102(7), 1106–1112 (2010).
   PubMed Web of Science ®Google Scholar
• Faiss S, Pape UF, Bohmig M et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors: the International Lanreotide and Interferon Alfa Study Group. J. Clin. Oncol. 21, 2689–2696 (2003).
   PubMed Web of Science ®Google Scholar
• Welin SV, Janson ET, Sundin A et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur. J. Endocrinol. 151(1), 107–112 (2004).
   PubMed Web of Science ®Google Scholar
• King J, Quinn R, Glenn DM et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113(5), 921–929 (2008).
   PubMed Web of Science ®Google Scholar
• Brizzi MP, Berruti A, Ferrero A et al. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A Phase II trial of the Piemonte oncology network. BMC Cancer 9, 388 (2009).
   PubMed Web of Science ®Google Scholar
• Haug AR, Auernhammer CJ, Wängler B et al. 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J. Nucl. Med. 51(9), 1349–1356 (2010).
   PubMedGoogle Scholar
• Swärd C, Bernhardt P, Ahlman H et al. [177Lu-DOTA 0-Tyr 3]-octreotate treatment in patients with disseminated gastroenteropancreatic neuroendocrine tumors: the value of measuring absorbed dose to the kidney. World J. Surg. 34(6), 1368–1372 (2010).
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T et al.; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 514–523 (2011).
   PubMed Web of Science ®Google Scholar